Skip to main content
NewslettersWatchlist

Solid Biosciences Inc(SLDB-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low5.21
Day High5.59
Open:5.26
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Solid Biosciences to Present at the Jefferies London Healthcare Conference
GlobeNewswire
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
Solid Biosciences to Participate at the Truist Securities BioPharma Symposium
GlobeNewswire
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MarketBeat
Are Gene Therapy Stocks The Market's Next Big Winners?
Business Wire
SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB
PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JVA, SLDB, FCRD, SPNE
Business Wire
SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB
Business Wire
SLDB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Solid Biosciences Inc. Is Fair to Shareholders
Globe Newswire
Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results
Globe Newswire
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Quality
Globe Newswire
Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy
Globe Newswire
Solid Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and 2-Year Efficacy and Safety Data from the Ongoing Phase I/II IGNITE DMD Clinical Trial of SGT-001
Globe Newswire
Solid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
Globe Newswire
Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
Globe Newswire
Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results
Globe Newswire
Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development
Globe Newswire
Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit
Globe NewsWire
Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
Globe NewsWire
Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
Globe NewsWire
Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

Profile

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.